Clinical Trial Update: Inhibition of Disease Progression in Hepatitis C-infected Patients With Compensated Liver Cirrhosis (P03811) (COMPLETED) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating inhibition of disease progression in hepatitis C patients with compensated liver cirrhosis was completed but terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C
• Liver Cirrhosis

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hepatitis C, Chronic, Liver Cirrhosis | Phase 3 | Status: TERMINATED